Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M993Revenue $M262Net Margin (%)-10.1Z-Score17.0
Enterprise Value $M889EPS $-0.4Operating Margin %-9.5F-Score4
P/E(ttm))0Cash Flow Per Share $0.5Pre-tax Margin (%)-9.9Higher ROA y-yN
Price/Book6.910-y EBITDA Growth Rate %0Quick Ratio4.3Cash flow > EarningsY
Price/Sales3.65-y EBITDA Growth Rate %0Current Ratio4.3Lower Leverage y-yY
Price/Cash Flow54.0y-y EBITDA Growth Rate %-506.7ROA % (ttm)-15.7Higher Current Ratio y-yN
Dividend Yield %0Insider Buy (3m)0ROE % (ttm)-19.3Less Shares Outstanding y-yY
Payout Ratio %0Shares Outstanding M31.7ROI % (ttm)1.3Gross Margin Increase y-yN

Gurus Latest Trades with GHDX

Number of guru portfolios checked: 84. (List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
GHDXDavid Swensen 2013-03-31 Sold Out -2.8%$26.72 - $29.65
($28.5)
$ 31.3110%Sold Out0
GHDXDavid Swensen 2012-12-31 Buy 2.8%$26.42 - $36.8
($30.13)
$ 31.314%New holding, 37861 sh.37,861
GHDXDavid Swensen 2011-03-31 Sold Out -0.93%$21.08 - $26.18
($23.29)
$ 31.3134%Sold Out0
GHDXDavid Swensen 2010-12-31 Buy 0.93%$13.18 - $23.52
($17.74)
$ 31.3176%New holding, 38243 sh.38,243
GHDXGeorge Soros 2006-12-31 Sold Out -0.23%$13.85 - $23.89
($17.5)
$ 31.3179%Sold Out0
GHDXGeorge Soros 2006-09-30 Buy 0.23%$11.16 - $14.38
($13)
$ 31.31141%New holding, 236371 sh.236,371
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

GHDX is held by these Gurus:

Premium Most recent portfolio changes are included for Premium Members only!


GHDX: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
Popovits Kimberly JPresident and CEO 2014-12-11Sell3,000$32.99-5.09view
Cole G BradleyCOO 2014-12-08Sell4,336$32.52-3.72view
Popovits Kimberly JPresident and CEO 2014-11-12Sell4,300$34.82-10.08view
Cole G BradleyCOO 2014-11-10Sell4,000$35.35-11.43view
LIVINGSTON RANDALL SDirector 2014-11-03Sell3,000$36.24-13.6view
Popovits Kimberly JPresident and CEO 2014-10-13Sell3,000$30.781.72view
Cole G BradleyCOO 2014-10-08Sell4,000$28.778.83view
Popovits Kimberly JPresident and CEO 2014-09-11Sell3,000$29.825view
Cole G BradleyCOO 2014-09-08Sell4,700$30.094.05view
Shak StevenEVP of R&D 2014-08-14Sell13,348$27.3614.44view

Press Releases about GHDX :

    Quarterly/Annual Reports about GHDX:

    News about GHDX:

    Articles On GuruFocus.com
    CEO of InVitae Corporation of Genomic Health Inc. Randal W. Scott Sold 30,000 Shares Jul 13 2012 
    Genomic Health Inc. (GHDX) President and CEO Kimberly J Popovits sells 8,000 Shares Mar 16 2011 
    Genomic Health Inc. (GHDX) CFO Dean L Schorno sells 1,000 Shares Mar 16 2011 
    Genomic Health Inc. (GHDX) Executive Chairman Randal W Scott sells 20,000 Shares Mar 14 2011 
    Genomic Health Inc. (GHDX) COO G Bradley Cole sells 2,500 Shares Mar 10 2011 
    Genomic Health Inc. (GHDX) President and CEO Kimberly J Popovits sells 8,000 Shares Feb 16 2011 
    Genomic Health Inc. (GHDX) President and CEO Kimberly J Popovits sells 8,000 Shares Feb 16 2011 
    Genomic Health Inc. (GHDX) CFO Dean L Schorno sells 1,000 Shares Feb 16 2011 
    Genomic Health Inc. (GHDX) Executive Chairman Randal W Scott sells 20,000 Shares Feb 14 2011 
    Genomic Health Inc. (GHDX) President and CEO Kimberly J Popovits sells 8,000 Shares Jan 19 2011 


    More From Other Websites
    Nasdaq stocks posting largest percentage decreases Dec 19 2014
    Claritas Genomics Appoints Patrick F. Terry as Chief Commercial Officer Dec 18 2014
    Oncotype DX® DCIS Score™ Represents Breakthrough in Personalizing Treatment of Pre-Invasive... Dec 12 2014
    Oncotype DX® DCIS Score™ Represents Breakthrough in Personalizing Treatment of Pre-Invasive... Dec 12 2014
    Genomic Health's Liquid Biopsy Tests Positive in Twin Studies Dec 11 2014
    Genomic Health Announces Presentation of First Prospective Outcomes Study of Oncotype DX® Breast... Dec 10 2014
    Genomic Health Advances Development of Novel Liquid Biopsy-Based Cancer Tests Dec 09 2014
    Genomic Health Advances Development of Novel Liquid Biopsy-Based Cancer Tests Dec 09 2014
    Genomic Health's Oncotype DX: Cancer Testing Made Easier Dec 04 2014
    Genomic Health (GHDX) Downgraded From Hold to Sell Dec 03 2014
    Oncotype DX® Predicts Outcomes in Prostate Cancer Patients, Significantly Changes Treatment... Dec 03 2014
    Oncotype DX® Predicts Outcomes in Prostate Cancer Patients, Significantly Changes Treatment... Dec 03 2014
    2014 San Antonio Breast Cancer Symposium to Feature Oncotype DX® DCIS Study in Press Program on... Dec 02 2014
    Genomic Health to Present at the 26th Annual Piper Jaffray Healthcare Conference Nov 26 2014
    Genomic Health to Present at the 26th Annual Piper Jaffray Healthcare Conference Nov 26 2014
    Results from Second Oncotype DX® Prostate Cancer Test Clinical Validation and First Decision Impact... Nov 19 2014
    Results from Second Oncotype DX® Prostate Cancer Test Clinical Validation and First Decision Impact... Nov 19 2014
    GENOMIC HEALTH INC Financials Nov 14 2014
    GENOMIC HEALTH INC Files SEC form 8-K, Change in Directors or Principal Officers Nov 10 2014
    10-Q for Genomic Health, Inc. Nov 08 2014

    Add Notes, Comments

    If you want to ask a question, or report a bug, please create a support ticket.

    User Comments

    No comment yet
    Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
    GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
    Free 7-day Trial
    FEEDBACK